Effect of liraglutide or glimepiride added to metformin on blood glucose control in subjects with type 2 diabetes
Phase 3
Completed
- Conditions
- Health Condition 1: null- Diabetes Mellitus, Type 2
- Registration Number
- CTRI/2008/091/000014
- Lead Sponsor
- ovo Nordisk AS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 896
Inclusion Criteria
1. Type 2 diabetes
2. Subjects diagnosed with type 2 diabetes and treated with one or more oral antidiabetic drugs (OADs) for the last 3 months
3. HbA1c: 7.0-11.0% (both incl.) for subjects on OAD alone
4. HbA1c: 7.0-10.0 % (both incl.) for subjects on OAD combination therapy
5. BMI less than 45.0 kg/m2
6.Age -above 18 Years
Exclusion Criteria
1. Treatment with insulin within the last 3 months prior to the trial
2. Impaired liver or/and renal function
3. Significant cardiovascular disease over the last 6 months
4. Known retinopathy or maculopathy
5. Recurrent major hypoglycaemia or hypoglycaemic unawareness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method